LegisTrack
Back to all bills
HRES 225119th CongressIn Committee

Supporting the designation of March as "Autoimmune Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research.

Introduced: Mar 14, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs

H. Res. 225 is a non-binding House resolution that expresses support for designating March as “Autoimmune Awareness Month.” It also endorses efforts by health care providers and autoimmune patient advocacy/education organizations to raise public awareness about autoimmune diseases and to increase funding for autoimmune disease research. The resolution emphasizes that autoimmune diseases are a large, diverse group of chronic conditions that can affect many parts of the body, are often difficult to diagnose, and currently lack cures. It argues that raising awareness and boosting research funding could improve diagnosis, treatment, and understanding of root causes. As a resolution, the bill does not authorize spending or create new programs. Rather, it signals Congressional support and could influence funding priorities, public awareness campaigns, and collaboration among researchers, clinicians, and patient groups. It was introduced in the House by Ms. Stevens and referred to the Committee on Energy and Commerce.

Key Points

  • 1Designates March as “Autoimmune Awareness Month” to educate the public about autoimmune diseases and the need for research funding, accurate diagnosis, and effective treatments.
  • 2Supports collaboration among health care providers and autoimmune patient advocacy/education organizations to increase awareness of causes and treatments.
  • 3Supports increasing funding for aggressive research to uncover root causes of autoimmune diseases and to improve diagnostic methods and treatments.
  • 4Highlights that autoimmune diseases comprise more than 100 conditions that can affect any organ or body system and are often chronic and debilitating.
  • 5Notes issues such as rising prevalence, high impact on women (approximately 80% of those affected), delays in diagnosis, and the need for better standardized diagnostic tests.

Impact Areas

Primary group/area affected: People with autoimmune diseases and their families, who may benefit from increased awareness, earlier diagnosis, and more robust research efforts.Secondary group/area affected: Health care providers, patient advocacy and education organizations, researchers, and research funders (e.g., NIH) who would be involved in awareness initiatives and research efforts.Additional impacts: A symbolic or aspirational shift in national priorities toward autoimmune disease research; potential influence on public awareness campaigns and cross-disciplinary collaboration, though no new funding or programs are created by this resolution alone.
Generated by gpt-5-nano on Nov 1, 2025